Ranibizumab
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Vascular endothelial growth factor A (VEGF-A) |
| Clinical data | |
| Trade names | Lucentis, others |
| Biosimilars | Ranibizumab-nuna, Ranibizumab-eqrn, Byooviz, Cimerli, Ranivisio, Raniviz, Susvimo, Ximluci |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607044 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravitreal injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | Approx. 9 days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2158H3282N562O681S12 |
| Molar mass | 48379.97 g·mol−1 |
| (what is this?) (verify) | |
Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis. Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006, and in the European Union in January 2007.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.